Eli Lilly | LLY - Ebit

Aktienkurs
883.96
Täglich Wechseln
-33.69 -3.67%
Monatlich
-3.53%
Jährlich
-0.07%
Q2 Prognose
865.04




Ebit Veränderung Datum
AbbVie USD 5.81B 4.36B 2025-12
Abbott USD 1.85B 684M 2026-03
ALKERMES USD -10.95M 100.03M 2025-12
Amgen USD 3.96B 464M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
Baxter International USD -214.2M 415.4M 2025-12
Biogen USD 659.6M 157M 2025-09
Bristol-Myers Squibb USD 3.47B 567M 2025-12
Coherus Biosciences USD -39.08M 3.65M 2025-12
Drreddys Laboratories INR 16.37B 3.5B 2025-12
Eli Lilly USD 8.99B 1.57B 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Glaxosmithkline GBP 2.3B 1.46B 2025-12
J&J USD 6.62B 1.51B 2026-03
Medtronic USD 1.74B 40M 2025-12
Merck USD 6.24B 1.32B 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Novartis USD 4.06B 530M 2025-12
Novartis USD 4.06B 413M 2025-12
Novo Nordisk DKK 32.38B 1.7B 2025-12
Perrigo USD 84.4M 9M 2025-12
Pfizer USD 4.65B 71M 2025-12
Phibro Animal Health USD 54.99M 2.36M 2025-12
Prestige Brands USD 82.49M 2.82M 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Roche Holding CHF 9.56B 2.1B 2025-12
Sanofi EUR 1.94B 239M 2026-03
Sanofi EUR 3.74B 2.23B 2025-09
United Therapeutics USD -14.6M 403.9M 2025-12
Zoetis USD 835M 140M 2025-12